462 related articles for article (PubMed ID: 22868340)
1. The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma.
Kim HS; Kim HR; Kim GM; Kim HS; Koh YW; Kim SH; Choi EC; Hong YK; Sung JH; Kim SM; Kim JH; Cho BC
Cancer Chemother Pharmacol; 2012 Oct; 70(4):539-46. PubMed ID: 22868340
[TBL] [Abstract][Full Text] [Related]
2. Induction chemotherapy with S-1 plus cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck.
Choi YJ; Chung JS; Shin HJ; Cho GJ; Wang SG; Lee BJ; Cho BM; Joo YD; Sohn CH
J Laryngol Otol; 2008 Aug; 122(8):848-53. PubMed ID: 18047761
[TBL] [Abstract][Full Text] [Related]
3. Triweekly reduced-dose docetaxel combined with cisplatin in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase II study.
Chang PM; Tzeng CH; Chen MH; Tsao CJ; Su WC; Hwang WS; Chang YF; Chang SY; Yang MH
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1477-84. PubMed ID: 21484308
[TBL] [Abstract][Full Text] [Related]
4. Modified docetaxel, cisplatin and fluorouracil therapy as the first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck cancer: a retrospective study.
Demirci NS; Aksoy S; Özdemir NY; Erdem GU; Ozcelik M; Tanrikulu E; Eren T; Bozkaya Y; Sahin S; Başol F; Aslan SA; Zengin N; Güllü İ
Curr Med Res Opin; 2017 Mar; 33(3):401-407. PubMed ID: 27817239
[TBL] [Abstract][Full Text] [Related]
5. Multicenter phase II study of weekly docetaxel, cisplatin, and S-1 (TPS) induction chemotherapy for locally advanced squamous cell cancer of the head and neck.
Bae WK; Hwang JE; Shim HJ; Cho SH; Lee KH; Han HS; Song EK; Yun HJ; Cho IS; Lee JK; Lim SC; Chung WK; Chung IJ
BMC Cancer; 2013 Mar; 13():102. PubMed ID: 23497365
[TBL] [Abstract][Full Text] [Related]
6. S-1 monotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck after progression on platinum-based chemotherapy.
Yokota T; Onozawa Y; Boku N; Hamauchi S; Tsushima T; Taniguchi H; Todaka A; Machida N; Yamazaki K; Fukutomi A; Yasui H
Jpn J Clin Oncol; 2011 Dec; 41(12):1351-7. PubMed ID: 21980053
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.
Schöffski P; Catimel G; Planting AS; Droz JP; Verweij J; Schrijvers D; Gras L; Schrijvers A; Wanders J; Hanauske AR
Ann Oncol; 1999 Jan; 10(1):119-22. PubMed ID: 10076732
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
Cho H; Nishiike S; Yamamoto Y; Takenaka Y; Nakahara S; Yasui T; Hanamoto A; Inohara H
Auris Nasus Larynx; 2015 Oct; 42(5):396-400. PubMed ID: 25721854
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma.
Adamo V; Ferraro G; Pergolizzi S; Sergi C; Laudani A; Settineri N; Alafaci E; Scimone A; Spano F; Spitaleri G
Oral Oncol; 2004 May; 40(5):525-31. PubMed ID: 15006626
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
[TBL] [Abstract][Full Text] [Related]
11. PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck.
Wirth LJ; Dakhil S; Kornek G; Axelrod R; Adkins D; Pant S; O'Brien P; Debruyne PR; Oliner KS; Dong J; Murugappan S
Oral Oncol; 2016 Oct; 61():31-40. PubMed ID: 27688102
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II study of s-1 plus cisplatin combination chemotherapy in patients with advanced/recurrent head and neck cancer.
Fujii M; Tomita K; Nishijima W; Tsukuda M; Hasegawa Y; Ishitoya J; Yamane H; Homma A; Tomita T
Jpn J Clin Oncol; 2010 Mar; 40(3):214-21. PubMed ID: 19934112
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of S-1 chemotherapy in recurrent/metastatic head and neck cancer.
Suzuki S; Ishikawa K
J Infect Chemother; 2009 Oct; 15(5):335-9. PubMed ID: 19856075
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck.
Vermorken JB; Licitra L; Stöhlmacher-Williams J; Dietz A; Lopez-Picazo JM; Hamid O; Hossain AM; Chang SC; Gauler TC
Eur J Cancer; 2013 Sep; 49(13):2877-83. PubMed ID: 23726971
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck.
Specht L; Larsen SK; Hansen HS
Ann Oncol; 2000 Jul; 11(7):845-9. PubMed ID: 10997812
[TBL] [Abstract][Full Text] [Related]
16. Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Shin DM; Glisson BS; Khuri FR; Hong WK; Lippman SM
Semin Oncol; 1998 Apr; 25(2 Suppl 4):40-4; discussion 45-8. PubMed ID: 9578061
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma.
Shin DM; Glisson BS; Khuri FR; Ginsberg L; Papadimitrakopoulou V; Lee JJ; Lawhorn K; Gillenwater AM; Ang KK; Clayman GL; Callender DL; Hong WK; Lippman SM
J Clin Oncol; 1998 Apr; 16(4):1325-30. PubMed ID: 9552033
[TBL] [Abstract][Full Text] [Related]
18. Phase II study with docetaxel and cisplatin in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Gedlicka C; Formanek M; Selzer E; Burian M; Kornfehl J; Fiebiger W; Cartellieri M; Marks B; Kornek GV
Oncology; 2002; 63(2):145-50. PubMed ID: 12239449
[TBL] [Abstract][Full Text] [Related]
19. A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma.
Wang HY; Yao ZH; Tang H; Zhao Y; Jin SL; Zhou WP; Yao SN; Yang SJ; Liu YY; Luo SX
Oncotarget; 2017 Jan; 8(5):7540-7547. PubMed ID: 27902478
[TBL] [Abstract][Full Text] [Related]
20. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
Worden FP; Moon J; Samlowski W; Clark JI; Dakhil SR; Williamson S; Urba SG; Ensley J; Hussain MH;
Cancer; 2006 Jul; 107(2):319-27. PubMed ID: 16779801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
